Newsroom

Newsroom - 2015

Glenmark Pharmaceuticals receives ANDA approval for Linezolid Tablets

Glenmark Pharmaceuticals announces the settlement of Paragraph IV litigation with Forest Laboratories

Glenmark Pharmaceuticals receives ANDA approval for Clotrimazole and Betamethasone Dipropionate Cream

Glenmark Pharmaceuticals receives tentative ANDA approval for Lacosamide Tablets

Glenmark’s Consolidated Revenue increases in Q2 FY 15-16

Glenmark announces Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler® in Europe.

Glenmark’s Bi-Specific Antibody - GBR 1302 to enter Phase I trials.

Glenmark Pharmaceuticals receives ANDA approval for Voriconazole Tablets

Glenmark Pharmaceuticals receives ANDA approval for Voriconazole Tablets

Glenmark’s novel monoclonal antibody GBR 830 to enter Phase 2 clinical studies in Atopic Dermatitis and Celiac Disease in US and Europe

Glenmark Pharmaceuticals receives ANDA approval for Drospirenone and Ethinyl Estradiol Tablet

Glenmark’s Consolidated Revenue increases in Q1 FY 15-16

Glenmark Pharmaceuticals receives ANDA approval for Levonorgestrel and Ethinyl Estradiol Tablets

Glenmark Pharmaceuticals receives ANDA approval for Calcipotriene Cream

Glenmark Pharmaceuticals receives ANDA approval for Desmopressin Acetate Tablets

Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene Cream

Glenmark Generics receives ANDA approval for Levonorgestrel and Ethinyl Estradiol Tablets

Glenmark receives final ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Tablets

Glenmark receives approval for generic Seretide® in Russia.

Glenmark announces approval and launch of Trandolapril & Verapamil Hydrochloride (HCl) Extended Release Tablets in the US.

Glenmark announces approval and launch of Ashlyna™ Extended.

Glenmark’s consolidated revenue increases for Q3 FY 14 – 15